4-Week, Multiple-dose, Dose-escalating Study In Patients With Type 2 Diabetes
| Status: | Recruiting |
|---|---|
| Conditions: | Diabetes, Diabetes |
| Therapuetic Areas: | Endocrinology |
| Healthy: | No |
| Age Range: | 18 - 70 |
| Updated: | 2/22/2019 |
| Start Date: | June 25, 2018 |
| End Date: | June 17, 2019 |
| Contact: | Pfizer CT.gov Call Center |
| Email: | ClinicalTrials.gov_Inquiries@pfizer.com |
| Phone: | 1-800-718-1021 |
A PHASE 1, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF MULTIPLE ESCALATING ORAL DOSES OF PF-06882961 IN ADULT SUBJECTS WITH TYPE 2 DIABETES MELLITUS
This is a dose-escalating study in patients with Type 2 diabetes on metformin. Participants
will receive an investigational product or placebo for 28 days.
will receive an investigational product or placebo for 28 days.
Inclusion Criteria:
- Type 2 diabetes treated with a stable dose of metformin at least 500 mg
- HbA1c value between 7.0 and 10.5%
Exclusion Criteria:
- Type 1 diabetes or secondary forms of diabetes
We found this trial at
3
sites
Click here to add this to my saved trials
Anaheim Clinical Trials, LLC Anaheim Clinical Trials (ACT) is a research center of excellence for...
Click here to add this to my saved trials
Click here to add this to my saved trials